|
Synonyms
|
Granulocyte/Macrophage Colony-Stimulating Factor, CSF-2, MGI-1GM, Pluripoietin-α
|
|
Species
|
Human
|
|
Accession
|
P04141
|
|
GeneID
|
1437
|
|
Source
|
Escherichia coli.
|
|
Molecular Weight
|
重组人类Granulocyte-Macrophage集落刺激因子蛋白Approximately 14.5 kDa, a single non-glycosylated polypeptide chain containing 127 amino acids.
|
|
Quantity
|
5µg/20µg/1000µg
|
|
AA Sequence
|
APARSPSPST QPWEHVNAIQ EARRLLNLSR DTAAEMNETV EVISEMFDLQ EPTCLQTRLE LYKQGLRGSL TKLKGPLTMM ASHYKQHCPP TPETSCATQI ITFESFKENL KDFLLVIPFD CWEPVQE
|
|
Purity
|
> 98 % by SDS-PAGE and HPLC analyses.
|
|
Biological Activity
|
重组人类Granulocyte-Macrophage集落刺激因子蛋白Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human TF-1 cells is less than 0.1 ng/ml, corresponding to a specific activity of > 1.0 × 107 IU/mg.
|
|
Physical Appearance
|
Sterile Filtered White lyophilized (freeze-dried) powder.
|
|
Formulation
|
Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
|
|
Endotoxin
|
Less than 1.0 EU/μg of rHuGM-CSF as determined by LAL method.
|
|
Reconstitution
|
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
|
|
Storage
|
This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.
|
|
重组人类Granulocyte-Macrophage集落刺激因子蛋白
|
|
|
SDS-PAGE
|
|
|
Reference
|
重组人类Granulocyte-Macrophage集落刺激因子蛋白1. Wang JM, Chen ZG, Colotta F, et al. 1988. Behring Inst Mitt: 270-3.
2. 1989. N Engl J Med, 320: 253-4.
3. Nissen-Druey C. 1989. Nouv Rev Fr Hematol, 31: 99-101.
4. Eager RandNemunaitis J. 2005. Mol Ther, 12: 18-27.
5. Tran T, Fernandes DJ, Schuliga M, et al. 2005. Br J Pharmacol, 145: 123-31.
|
|
Background
|
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) is secreted by a number of different cell types (including activated T cells, B cells, macrophages, mast cells, endothelial cells and fibroblasts) in response to cytokine or immune and inflammatory stimulation. It was initially characterized as a growth factor that can support the in vitro colony formation of granulocyte-macrophage progenitors and has functions of stimulates the growth and differentiation of hematopoietic precursor cells from various lineages. GM-CSF has also been reported to have a functional role on non-hematopoietic cells and can induce human endothelial cells to migrate and proliferate. Additionally, it can stimulate the proliferation of a number of tumor cell lines, including osteogenic sarcoma, carcinoma and adenocarcinoma cell lines. Human GM-CSF shares 54 % sequences identity with mouse GM-CSF, but has no biological effects across species. GM-CSF is used as a medication to stimulate the production of white blood cells following chemotherapy and has also recently been evaluated in clinical trials for its potential as a vaccine adjuvant in HIV-infected patients.
|
